PMV PHARMACEUTICALS INC (PMVP) Stock News

USA - Nasdaq - NASDAQ:PMVP - US69353Y1038 - Common Stock

1.29 USD

0 (0%)

Last: 12/4/2025, 10:20:01 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PMVP Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

a month ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

2 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

3 months ago - By: Benzinga

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

3 months ago - By: Benzinga - Mentions: ACTU CAMP GNPX TVTX ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a year ago - By: BusinessInsider

News Image

PMVP Stock Earnings: PMV Pharma Beats EPS for Q2 2024

a year ago - By: InvestorPlace

PMVP Stock Earnings: PMV Pharma Beats EPS for Q2 2024

2 years ago - By: InvestorPlace

PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024

3 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

4 months ago - By: The Motley Fool

PMV Pharmaceuticals (PMVP) Q2 Loss Jumps

2 years ago - By: BusinessInsider

News Image

PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024

4 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

6 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

7 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

9 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

10 months ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

a year ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

a year ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial

2 years ago - By: Foundation Medicine

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

2 years ago - By: PMV Pharmaceuticals, Inc.

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference

2 years ago - By: Seeking Alpha

PMV to focus on lead drug, slashes workforce by 30% (NASDAQ:PMVP)

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

2 years ago - By: Seeking Alpha

PMV Pharmaceuticals names Michael Carulli as CFO (NASDAQ:PMVP)

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

2 years ago - By: Seeking Alpha

Ladenburg Thalmann starts PMV Pharmaceuticals at buy (NASDAQ:PMVP)

2 years ago - By: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights